Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: peptide cancer therapeutics - EpiAxis Therapeutics

Next Previous
Search
Drug Profile

Research programme: peptide cancer therapeutics - EpiAxis Therapeutics

Latest Information Update: 31 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Canberra
  • Class Antineoplastics; Peptides
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Protein kinase C theta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Aug 2022 EpiAxis Therapeutics and Peptilogics entered into a collaboration agreement for peptide cancer therapeutics
  • 02 Aug 2022 EpiAxis Therapeutics has patent protection for use of all LSD1 inhibitors in combination settings for metastatic cancer in the US (EpiAxis Therapeutics website, August 2022)
  • 30 Jul 2022 Preclinical trials in Cancer (Metastatic disease) in Australia (unspecified route) (EpiAxis Therapeutics website, August 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top